Should I buy or sell Roivant Sciences stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Roivant Sciences in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ROIV shares. View ROIV analyst ratings or view top-rated stocks .

What is Roivant Sciences' stock price target for 2024?

9 Wall Street research analysts have issued 1-year price objectives for Roivant Sciences' shares. Their ROIV share price targets range from $10.00 to $23.00. On average, they anticipate the company's stock price to reach $15.33 in the next year. This suggests a possible upside of 68.7% from the stock's current price. View analysts price targets for ROIV or view top-rated stocks among Wall Street analysts .

How have ROIV shares performed in 2023?

Roivant Sciences' stock was trading at $7.99 on January 1st, 2023. Since then, ROIV shares have increased by 13.8% and is now trading at $9.09. View the best growth stocks for 2023 here .

When is Roivant Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 12th 2024. View our ROIV earnings forecast .

How were Roivant Sciences' earnings last quarter?

Roivant Sciences Ltd. (NASDAQ:ROIV) issued its quarterly earnings data on Monday, August, 14th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by $0.10. The firm earned $21.60 million during the quarter, compared to the consensus estimate of $24.49 million. Roivant Sciences had a negative net margin of 951.77% and a negative trailing twelve-month return on equity of 73.04%. The company's quarterly revenue was up 402.3% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.48) earnings per share.

What ETFs hold Roivant Sciences' stock?

ETFs with the largest weight of Roivant Sciences (NASDAQ:ROIV) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH) , Virtus LifeSci Biotech Products ETF (BBP) , Direxion Moonshot Innovators ETF (MOON) , SPDR S&P Biotech ETF (XBI) , Direxion Daily S&P Biotech Bull 3x Shares (LABU) , Invesco Nasdaq Biotechnology ETF (IBBQ) , Invesco Dorsey Wright Momentum ETF (PDP) and First Trust Nasdaq Pharmaceuticals ETF (FTXH) .

Who are Roivant Sciences' major shareholders?

Roivant Sciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include SB Investment Advisers UK Ltd. (9.46%), FMR LLC (5.04%), Morgan Stanley (2.50%), Rubric Capital Management LP (1.36%), Adage Capital Partners GP L.L.C. (0.80%) and Loomis Sayles & Co. L P (0.26%). Insiders that own company stock include Eric Venker , Financial Lp Qvt, Global Investors Lp Viking, Keith S Manchester, Matthew Gline, Pharma Technologies Ltd Dexcel, Rakhi Kumar , Richard Pulik, Sciences Ltd Roivant, Svf Investments (Uk) Ltd and Vivek Ramaswamy. View institutional ownership trends .

How do I buy shares of Roivant Sciences?

Shares of ROIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Roivant Sciences Stock Price, News & Analysis (NASDAQ:ROIV)

$9.09

-0.01 (-0.11%)

(As of 11/28/2023 ET)

Compare

Today's Range: $8.88
▼
$9.15
50-Day Range: $8.38
▼
$13.19
52-Week Range: $5.01
▼
$13.24

Volume: 7.08 million shs
Average Volume: 4.50 million shs
Market Capitalization: $7.31 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.33

Roivant Sciences MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.89 Rating Score
Upside/Downside: 68.7% Upside
$15.33 Price Target
Short Interest: Healthy
5.49% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.16
Based on 12 Articles This Week
Insider Trading: Selling Shares
$221.24 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.55) to ($1.39) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.44 out of 5 stars

Medical Sector

193rd out of 949 stocks

Pharmaceutical Preparations Industry

78th out of 435 stocks

4.4

Analyst's Opinion

Consensus Rating
Roivant Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $15.33, Roivant Sciences has a forecasted upside of 68.7% from its current price of $9.09.
Amount of Analyst Coverage
Roivant Sciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
5.49% of the float of Roivant Sciences has been sold short.
Short Interest Ratio / Days to Cover
Roivant Sciences has a short interest ratio ("days to cover") of 4.6.
Change versus previous month
Short interest in Roivant Sciences has recently decreased by 10.11%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Roivant Sciences does not currently pay a dividend.
Dividend Growth
Roivant Sciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ROIV.

1.0

News and Social Media Coverage

News Sentiment
Roivant Sciences has a news sentiment score of -0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for Roivant Sciences this week, compared to 5 articles on an average week.
Search Interest
Only 2 people have searched for ROIV on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Roivant Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Roivant Sciences insiders have sold 281.45% more of their company's stock than they have bought. Specifically, they have bought $58,000,008.00 in company stock and sold $221,241,743.00 in company stock.
Percentage Held by Insiders
Only 4.60% of the stock of Roivant Sciences is held by insiders.
Percentage Held by Institutions
64.76% of the stock of Roivant Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Roivant Sciences are expected to grow in the coming year, from ($1.55) to ($1.39) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Roivant Sciences is -6.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Roivant Sciences is -6.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Roivant Sciences has a P/B Ratio of 4.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Roivant Sciences Stock (NASDAQ:ROIV)

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

ROIV Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ROIV Stock News Headlines

November 29, 2023 | markets.businessinsider.com

Optimistic Outlook for Roivant Sciences Despite Lupus Trial Setback: Tsao Maintains Buy Rating

November 28, 2023 | finance.yahoo.com

Roivant’s Matt Gline on raising capital and biotech’s outlook in 2024

November 28, 2023 | RYSE INC. (Ad)

Secure your stake in the Smart Home industry.

Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.

November 28, 2023 | finance.yahoo.com

Roivant’s Matt Gline on raising capital and biotech’s outlook for 2024

November 28, 2023 | markets.businessinsider.com

Hold Rating Maintained for Roivant Sciences Amidst Phase 2 Trial Setback and Upcoming Catalysts

November 28, 2023 | finance.yahoo.com

Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential

November 27, 2023 | proactiveinvestors.com

Roivant Sciences unable to determine effectiveness of lupus drug in Phase 2 study

November 27, 2023 | msn.com

Why Is Vivek Ramaswamy-Founded Roivant Sciences Stock Trading Lower Today?

November 28, 2023 | RYSE INC. (Ad)

Secure your stake in the Smart Home industry.

Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.

November 27, 2023 | msn.com

Roivant slides on failed Phase 2 study for lupus drug candidate

November 27, 2023 | markets.businessinsider.com

Roivant: Oral Brepocitinib Fails To Meet Primary Endpoint In Phase 2 Study

November 27, 2023 | reuters.com

Roivant Sciences' lupus drug fails to reduce symptoms in mid-stage study

November 27, 2023 | msn.com

Roivant Sciences shares drop as lupus treatment misses trial goal

November 27, 2023 | finance.yahoo.com

Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus

November 17, 2023 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Invitae (NVTA), Roivant Sciences (ROIV) and Exact Sciences (EXAS)

November 15, 2023 | finance.yahoo.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Analysts Just Cut Their EPS Forecasts Substantially

November 15, 2023 | markets.businessinsider.com

Roivant Sciences: Promising Future Growth Predicated on Product Expansion and Solid Financial Health

November 14, 2023 | finance.yahoo.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Q2 2023 Earnings Call Transcript

November 14, 2023 | markets.businessinsider.com

Hold Rating on Roivant Sciences Amid Revenue Shortfall and Pipeline Uncertainties

November 14, 2023 | finance.yahoo.com

Q2 2024 Roivant Sciences Ltd Earnings Call

November 14, 2023 | markets.businessinsider.com

Buy Rating for Roivant Sciences Despite Slower Launch: An Analysis of Growth Potential and Competitive Advantages

November 13, 2023 | finance.yahoo.com

Roivant Sciences Ltd Reports Q2 Financial Results and Business Progress

November 13, 2023 | seekingalpha.com

Roivant Sciences Ltd. 2023 Q2 - Results - Earnings Call Presentation

November 13, 2023 | msn.com

Roivant Sciences GAAP EPS of -$0.40 misses by $0.09, revenue of $37.1M beats by $9.98M

November 13, 2023 | finance.yahoo.com

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update

November 12, 2023 | markets.businessinsider.com

Roivant Sciences earnings preview: what Wall Street is expecting

November 10, 2023 | morningstar.com

Roivant Sciences Ltd Ordinary Shares

See More Headlines

Receive ROIV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Roivant Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/14/2023
Today: 11/28/2023
Next Earnings (Estimated): 2/12/2024
Fiscal Year End: 3/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ROIV
CUSIP: N/A
CIK: 1635088
Web: roivant.com
Phone: 44-20-7400-3347
Fax: N/A
Employees: 904
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $15.33
High Stock Price Target: $23.00
Low Stock Price Target: $10.00
Potential Upside/Downside: +68.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.89
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.32)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-1,009,030,000.00
Net Margins: -951.77%
Pretax Margin: -1,177.62%
Return on Equity: -73.04%
Return on Assets: -47.29%

Debt

Debt-to-Equity Ratio: 0.29
Current Ratio: 5.84
Quick Ratio: 5.84

Sales & Book Value

Annual Sales: $61.28 million
Price / Sales: 119.25
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.11 per share
Price / Book: 4.31

Miscellaneous

Outstanding Shares: 803,920,000
Free Float: 766,941,000
Market Cap: $7.31 billion
Optionable: Not Optionable
Beta: 1.32

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. Matthew Gline (Age 39)
CEO & Director
Comp: $1.77M
Dr. Eric Venker M.D. (Age 36)
Pharm.D., President & COO
Comp: $1.28M
Dr. Mayukh Sukhatme M.D. (Age 47)
President & Chief Investment Officer
Comp: $1.72M
Mr. Richard Pulik (Age 44)
Chief Financial Officer
Ms. Rakhi Kumar (Age 43)
Chief Accounting Officer
Dr. Huafeng Xu Ph.D.
Chief Technology Officer
Mr. Josh Chen
General Counsel
Ms. Kelly Graff
Head of People
Ms. Marianne L. Romeo (Age 55)
Head of Global Transactions & Risk Management
Mr. Alex Gasner
Executive Vice President of Roivant Health

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ROIV Stock Analysis - Frequently Asked Questions

Should I buy or sell Roivant Sciences stock right now?: 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Roivant Sciences in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ROIV shares.
View ROIV analyst ratings or view top-rated stocks.
What is Roivant Sciences' stock price target for 2024?: 9 Wall Street research analysts have issued 1-year price objectives for Roivant Sciences' shares. Their ROIV share price targets range from $10.00 to $23.00. On average, they anticipate the company's stock price to reach $15.33 in the next year. This suggests a possible upside of 68.7% from the stock's current price.
View analysts price targets for ROIV or view top-rated stocks among Wall Street analysts.
How have ROIV shares performed in 2023?: Roivant Sciences' stock was trading at $7.99 on January 1st, 2023. Since then, ROIV shares have increased by 13.8% and is now trading at $9.09.
View the best growth stocks for 2023 here.
When is Roivant Sciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, February 12th 2024.
View our ROIV earnings forecast.

How were Roivant Sciences' earnings last quarter?: Roivant Sciences Ltd. (NASDAQ:ROIV) issued its quarterly earnings data on Monday, August, 14th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by $0.10. The firm earned $21.60 million during the quarter, compared to the consensus estimate of $24.49 million. Roivant Sciences had a negative net margin of 951.77% and a negative trailing twelve-month return on equity of 73.04%. The company's quarterly revenue was up 402.3% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.48) earnings per share.
What ETFs hold Roivant Sciences' stock?: ETFs with the largest weight of Roivant Sciences (NASDAQ:ROIV) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Virtus LifeSci Biotech Products ETF (BBP), Direxion Moonshot Innovators ETF (MOON), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco Nasdaq Biotechnology ETF (IBBQ), Invesco Dorsey Wright Momentum ETF (PDP) and First Trust Nasdaq Pharmaceuticals ETF (FTXH).
Who are Roivant Sciences' major shareholders?: Roivant Sciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include SB Investment Advisers UK Ltd. (9.46%), FMR LLC (5.04%), Morgan Stanley (2.50%), Rubric Capital Management LP (1.36%), Adage Capital Partners GP L.L.C. (0.80%) and Loomis Sayles & Co. L P (0.26%). Insiders that own company stock include Eric Venker, Financial Lp Qvt, Global Investors Lp Viking, Keith S Manchester, Matthew Gline, Pharma Technologies Ltd Dexcel, Rakhi Kumar, Richard Pulik, Sciences Ltd Roivant, Svf Investments (Uk) Ltd and Vivek Ramaswamy.
View institutional ownership trends.
How do I buy shares of Roivant Sciences?: Shares of ROIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ROIV) was last updated on 11/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Roivant Sciences Stock Price, News & Analysis (NASDAQ:ROIV)

Roivant Sciences MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Roivant Sciences Stock (NASDAQ:ROIV)

ROIV Stock Price History

ROIV Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ROIV Stock Analysis - Frequently Asked Questions

Overall MarketRank^™